Physician profile
Sharon Smith
NPI 1558923649
$2,718.53
in general payments reported to CMS, 2019-2025
20 companies · $524 in 2025
The $524 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $861 · 2023: $963 · 2024: $371 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,857.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $299.96 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $271.07 | 2022-2023 | Rexulti |
| Neurocrine Biosciences, INC. | $261.36 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.86 | 2022-2024 | Caplyta |
| Abbvie INC. | $146.61 | 2023-2024 | |
| Genentech USA, INC. | $137.01 | 2023 | Ocrevus |
| Glaxosmithkline, LLC. | $124.72 | 2022 | |
| Inspire Medical Systems, INC. | $121.66 | 2023 | Inspire |
| Horizon Therapeutics Plc | $119.11 | 2023 | Krystexxa |
| Tris Pharma INC | $118.70 | 2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Gilead Sciences, INC. | $116.15 | 2024 | |
| Scynexis, INC. | $116.15 | 2022 | |
| Kyowa Kirin, INC. | $115.36 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.36 | 2023 | Gammagard |
| Viiv Healthcare Company | $114.40 | 2023 | Apretude |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $105.33 | 2025 | Dupixent |
| Astellas Pharma US INC | $96.96 | 2023 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $96.07 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $64.30 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.